MD Anderson research highlights for May 10, 2023

Featuring combination therapies for ALL, AML, kidney and pancreatic cancer, plus novel data science tools to identify cancer and predict immunotherapy response

2023-05-10

(Press-News.org) HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

Recent developments include a combination therapy for acute lymphoblastic leukemia, new insights into the evolution of anaplastic thyroid cancer, a promising new treatment approach for PTEN/p53-deficient pancreatic cancer, a novel pan-species artificial intelligence model to detect cancer cells, a neoadjuvant combination therapy to improve disease-free survival in kidney cancer, combination therapies to overcome treatment resistance in acute myeloid leukemia, and a bioinformatics tool for predicting immunotherapy treatment response.

Mini-Hyper-CVD regimen with inotuzumab and blinatumomab improves survival for patients with relapsed ALL
Adults with relapsed/refractory acute lymphoblastic leukemia (ALL) historically have experienced poor outcomes when treated with intensive chemotherapy. Researchers led by Hagop Kantarjian, M.D., explored the addition of blinatumomab to low-intensity mini-Hyper-CVD chemotherapy with inotuzumab ozogamicin in a Phase II study. The study demonstrated the combination was safe and effective in patients with ALL. Among 110 patients, the combination resulted in a complete response rate of 83% and an absence of measurable residual disease in 82% of patients. Median overall survival (OS) was 17 months, and the three-year OS rate was 40% with a median follow-up of 48 months. The OS rate with mini-Hyper-CVD and inotuzumab alone was 34%, and the additional dose of blinatumomab improved the three-year OS rate to 54%. These long-term follow-up data confirmed the safety and efficacy of this regimen and suggest blinatumomab may further improve outcomes. Learn more in The Journal of Hematology & Oncology.

New model improves understanding of anaplastic transformation in thyroid cancer
Patients with anaplastic thyroid cancer (ATC) — which often results from a transformation of pre-existing differentiated thyroid cancer — have a low survival rate, highlighting a significant unmet clinical need to better understand this rare, aggressive disease and to develop effective treatment options. Researchers led by Jennifer Rui Wang, M.D., Ph.D., and Stephen Y. Lai, M.D., Ph.D., investigated this transformation using single-cell transcriptomes and genetic alteration data from patients with different thyroid cancer subtypes to create a model that tracks the evolution of ATC progression. They identified key milestones in the sequential programming of tumor cells and provided further insights into cell-cell signaling in the tumor microenvironment during ATC transformation. These discoveries can help the development of new therapeutic strategies to improve patient survival. Learn more in the Journal of Clinical Investigation.

Combination therapy shows promise in preclinical models of PTEN/p53-deficient prostate cancer
Patients with advanced castration-resistant prostate cancer do not respond well to androgen deprivation therapy or immunotherapy, especially if they have mutations or defects in tumor suppressors PTEN and p53. The immune checkpoint protein B7-H3 is overexpressed in advanced prostate cancer, but its role is poorly understood. Researchers led by Wei Shi, Ph.D., and Di Zhao, Ph.D., identified B7-H3 as a novel immunotherapy target in PTEN/TP53-deficient prostate cancer and uncovered its function in tumor progression and immunosuppression. Inhibiting B7-H3 using a monoclonal antibody in combination with PD-L1 or CTLA-4 blockade demonstrated significant tumor-suppressing activity in preclinical models, emphasizing this strategy as a viable option that merits further investigation in clinical studies. Learn more in Science Translational Medicine.

Novel pan-species AI atlas provides insights into the evolution of cancer development across species
Comparative oncology — the study of cancer across species — can provide insights into evolutionary mechanisms behind cancer development in humans and non-human animals, while also highlighting potential therapeutic strategies for human cancer treatments and animal conservation efforts. In a first-of-its-kind study, researchers led by Yinyin Yuan, Ph.D., used an artificial intelligence (AI) algorithm trained to recognize tumor cells, lymphocytes and stromal cells in human lung cancer samples taken from the Tracking Cancer Evolution Through Therapy (TRACERx) study. They applied this AI model to 120 tumor samples across 20 animal species, building a pan-species cancer digital pathology atlas that was highly accurate at classifying cancer cells, especially in canine transmissible venereal tumors (94% accurate) and Tasmanian devil facial tumor disease (88% accurate). This study highlights the potential of this pan-species AI model for identifying prognostic indicators of cancer in both animals and humans that could lead to further advances in the development of viable treatments in veterinary medicine and comparative oncology. Learn more in Nature Communications.

Kidney cancer treated with neoadjuvant sitravatinib plus nivolumab shows immune responses
Complete or partial surgical removal of the kidney (nephrectomy) is the current curative standard of care for locally advanced clear cell renal cell carcinoma (ccRCC), yet 20-40% of patients will develop metastases after successful surgery. Immune checkpoint therapy and tyrosine kinase inhibitors, such as sitravatinib, given prior to surgery have the potential to improve outcomes in patients with ccRCC. Researchers led by Jose Karam, M.D., and Pavlos Msaouel, M.D., Ph.D., conducted a Phase II study to evaluate the efficacy and safety of pre-surgical, or neoadjuvant, sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced ccRCC. While the objective response rate was only 11.8%, the 24-month disease-free survival probability was 88%. Blood and tissue analyses showed changes in the tumor microenvironment, resulting in an immunologically active tumor by the time of surgery. The study suggests future neoadjuvant trials should prioritize long-term survival endpoints such as disease-free survival. Learn more in Nature Communications.

Combination therapy targets senescent cells to overcome chemotherapy resistance in AML
Acute myeloid leukemia (AML) with overexpression of BCL-2 anti-apoptotic proteins is associated with aggressive disease progression and resistance to chemotherapy. While treatment with the BCL-2 inhibitor venetoclax plus chemotherapy results in high response rates, most patients eventually relapse, highlighting a need for more effective treatments. Recent findings have shown that chemoresistance is associated with cellular senescence, which occurs when cells stop dividing but avoid death, via upregulation of both BCL-XL and BCL-2 activity. Researchers led by Qi Zhang, M.D., Ph.D., examined the use of PROTAC 753B, a dual BCL-XL/BCL-2 inhibitor, to effectively eliminate these senescent cells both in vitro and in vivo. These results suggest the drug has potential as a viable therapeutic strategy to overcome chemotherapy resistance in AML. Learn more in Haematologica.

Novel triplet regimen delivers promising results in patients with IDH1-mutated acute myeloid leukemia
The current frontline combination therapy for patients with high-risk IDH1-mutated acute myeloid leukemia (AML) is effective, but relapses remain common for patients. In a first-of-its-kind study, researchers led by Courtney DiNardo, M.D., evaluated the safety and efficacy of ivosidenib and venetoclax as an oral doublet regimen and ivosidenib, venetoclax and azacytidine as a triplet combination. The overall composite remission rate across all cohorts on the study was 87%. The minimal residual disease negativity rate by flow cytometry was 75%, and IDH1 clearance occurred in 86% of patients who received the triplet combination. The treatment was safe and well tolerated by patients. Researchers are hopeful that these combinations will lead to deeper responses and long-lasting remissions for patients and are currently enrolling patients in the Phase II portion of the trial. Learn more in Blood Cancer Discovery.

Novel integrated bioinformatics tool may help predict response to immunotherapy
The effectiveness of immunotherapy can depend on various factors within the tumor microenvironment, underscoring a need to understand and identify interactions between tumor and immune cells to more accurately predict treatment response. While some bioinformatics tools can help identify immune signatures in tumors, no statistically validated tools are currently capable of examining combinations of tumor-immune interactions. Researchers led by Behnaz Bozorgui, Ph.D., and Anil Korkut, Ph.D., developed an integrated bioinformatics tool, resource and web application — Immuno-oncology gene interaction Maps (ImogiMap) — to more efficiently find interactions between tumor cells and immune checkpoints in the tumor microenvironment. Researchers applied the ImogiMap algorithm to endometrial and basal-like breast cancers to generate novel immune-tumor interactions and actionable targets, which help identify patients most likely to respond to immunotherapy. This tool can also be applied to other types of cancer. Learn more in Communications Biology.

Recent awards and honors

Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics, received the Flance-Karl Award from the American Surgical Association Eduardo Bruera, M.D., chair of Palliative Care Medicine, was inducted into the 2023 Class of OncLive’s Giants of Cancer Care®. Dimitrios Kontoyiannis, M.D., Ph.D., deputy division head of Internal Medicine, and Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics, were inducted into the Association of American Physicians (AAP) In case you missed it
Read below to catch up on recent MD Anderson press releases.

MD Anderson researchers Helen Piwnica-Worms and Richard Wood elected to National Academy of Sciences MD Anderson and Generate:Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI MD Anderson’s Hagop Kantarjian, M.D., awarded highest honor from American Society of Clinical Oncology

- 30 -

END

ELSE PRESS RELEASES FROM THIS DATE:

Millions of U.S. households may struggle to afford basic water services

2023-05-10

A new analysis suggests that about one in seven households across the U.S. may face financial hardship in paying for access to water and wastewater services. Lauren Patterson and colleagues at Duke University, North Carolina, present these findings in the open-access journal PLOS Water. U.S. households pay utilities for access to water for drinking, cooking, cleaning, and sanitation, as well as for wastewater services. However, in recent years, the cost of these services has increased alongside a widening income gap, fueling affordability concerns. ...

Data from Argonne’s Advanced Photon Source provides foundation for first US approved RSV vaccine

2023-05-10

Respiratory syncytial virus (RSV) is a highly contagious disease that affects millions of people each year around the world, resulting in an estimated 160,000 deaths. In the United States, severe RSV causes 6,000 to 10,000 deaths among people 65 years of age or older. On May 3, the U.S. Food and Drug Administration approved Arexvy, an RSV vaccine developed by pharmaceutical company GSK plc, formerly GlaxoSmithKline plc. It is the first RSV vaccine to be approved in the United States, and according to GSK’s press release, the first for older adults to be approved anywhere in the world. This is a ...

New procedure allows micro-printing inside existing materials with greater accuracy

2023-05-10

3D printers form objects by layering melted plastic or metal, but this only works on large scales. What you need to fabricate microdevices for which the layering step is not feasible? What if it were possible to print directly into the bulk of an existing three-dimensional material? The research groups of Lynford Goddard and Paul Braun, professors at the University of Illinois Urbana-Champaign, have been collaborating to develop such a process. They use the technique of multiphoton lithography to print inside an existing ...

Purdue April Consumer Food Insights report explores role of dollar stores in food landscape

2023-05-10

Purdue April Consumer Food Insights report explores role of dollar stores in food landscape A market for an expanded grocery selection at dollar stores potentially exists, especially with consumers who live less than 10 minutes away, according to data reported in the April Consumer Food Insights report. The survey-based report out of Purdue University’s Center for Food Demand Analysis and Sustainability assesses food spending, consumer satisfaction and values, support of agricultural and food policies, and trust in information sources. Purdue experts conducted and evaluated ...

Using reflections to see the world from new points of view

2023-05-10

As a car travels along a narrow city street, reflections off the glossy paint or side mirrors of parked vehicles can help the driver glimpse things that would otherwise be hidden from view, like a child playing on the sidewalk behind the parked cars. Drawing on this idea, researchers from MIT and Rice University have created a computer vision technique that leverages reflections to image the world. Their method uses reflections to turn glossy objects into “cameras,” enabling a user to see the world as if they were looking through the “lenses” of everyday objects like a ceramic coffee mug or a metallic ...

Stimulating hope: Personalizing treatment options for depression

2023-05-10

Artificial intelligence. Gene editing. mRNA vaccines. It’s safe to say the past few decades have felt like the next big wave of medicine. However, what continues to be needed in virtually every field is a personalized approach to care. That’s certainly needed when it comes to using transcranial magnetic stimulation (TMS) to treat depression, said Medical University of South Carolina Distinguished University Professor Mark George, M.D. TMS uses a magnet to increase brain activity in ...

Gene p16 drives colorectal cancer emerging as a target for potential therapies

2023-05-10

Colorectal cancer is the fourth most common and second deadliest cancer. How colorectal cancer develops is not well understood, but a team led by researchers at Baylor College of Medicine reports in the Journal of Experimental & Clinical Cancer Research that silencing the gene p16, even though the DNA itself does not change, can drive colorectal cancer progression in animal models. The researchers also revealed a strategy that reduced tumor growth and improved survival in tumor-bearing mice, opening new possibilities for future targeted therapies in patients with gene p16 alterations. “Years of research have shown ...

New database offers insight into consequences of language loss

2023-05-10

New database offers insight into consequences of language loss Languages, like animal species, can go extinct. More than half of the world’s approximately 7,000 signed and spoken languages are currently endangered. And without intervention they are likely to become extinct, meaning nobody will speak or sign them any longer. While language loss is happening across the world, the costs vary strikingly in different places, according to a new study co-authored by Yale linguist Claire Bowern. Regions where all Indigenous language are endangered — including parts of South America and the United States — ...

Bigger isn’t always better: Size of research teams does not equate to better research outcomes, finds new study

2023-05-10

Having a large research team isn’t linked to producing higher quality research, finds a new study from the University of Surrey which analysed data from 1.4 million academic papers. Professor Sorin Krammer, lead author of the study and Professor of Strategy and International Business at the University of Surrey, said: “Despite the prevalence of large teams in research, there is still a lack of a good understanding of how their size and diversity affects their performance.” “Our ...

The acute problem of chronic disease

2023-05-10

In medicine and science, the term “pathogenesis” describes the origin and development of disease. There is not, however, a broadly accepted term to describe the other half of the equation: the process of healing and recovery. In a new and far-reaching paper, published May 10, 2023 in the journal Mitochondrion, Robert K. Naviaux, MD, PhD, professor of Medicine, Pediatrics and Pathology at UC San Diego School of Medicine, proposes both a term and, more importantly, outlines the array of processes and players, beginning with cellular mitochondria, that drive the healing process – and whose dysfunction underlies chronic illnesses from diabetes ...